Xiaoliang Sang

Xiaoliang Sang is the current General Manager of SCIEX China. Prior to joining SCIEX, Xiaoliang served as the Regional Commercial GM for Gene & Cell Therapy Asia at Cytiva from April 2020 to October 2020. In this role, they were responsible for creating a strategic plan and road map to grow and develop in the Cell & Gene Therapy sector, via unique product platform, enterprise solution & digital solutions. Xiaoliang also rebuilt, developed and coached Asia team that foster & sustains strategic relationships with clients, to drive the highest levels of clients centric it’s that enable partners to achieve their objectives in this fast paced & exciting industry.

Prior to their role at Cytiva, Xiaoliang spent 16 years at GE Healthcare, where they most recently served as the Region GM for Asia Cell & Gene Therapy from August 2004 to March 2020. In this role, Xiaoliang was responsible for creating a strategic plan and road map to grow and develop in the Cell & Gene Therapy sector, via unique product platform, enterprise solution & digital solutions. Xiaoliang also rebuilt, developed and coached Asia team that foster & sustains strategic relationships with clients, to drive the highest levels of clients centric it’s that enable partners to achieve their objectives in this fast paced & exciting industry.

Xiaoliang began their career as a Sales Representative at Roche from April 2003 to March 2004.

Xiaoliang Sang has a bachelor's degree in biology from Zhejiang University and a Mini MBA from China Europe International Business School (CEIBS).

Xiaoliang Sang works with Kerry Larkin - VP, Strategic Marketing, Frank Maloto - VP, Global Danaher Business System & PMO, and Nichole Riek - VP, Quality & Regulatory Affairs. Xiaoliang Sang reports to Joe Fox, President.